Navigation Links
Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
Date:11/21/2011

CAMBRIDGE, England, November 21, 2011 /PRNewswire/ --

Phase I Single Dose Study Data Demonstrate Ideal Pharmacokinetic Profile and Excellent Safety and Tolerability

Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.

The trial is a randomised, placebo controlled Phase I study to investigate the pharmacokinetics, safety and tolerability of orally administered multiple dose regimens of CNV2197944 in both young and elderly volunteers. CNV2197944 is proposed for development initially as a treatment for neuropathic pain and pain associated with osteoarthritis. The study is expected to conclude in 2Q 2012.

The first human single ascending dose Phase I study with orally administered CNV2197944 was recently completed. CNV2197944 was shown to be well absorbed, with an ideal pharmacokinetic profile for the target indication of chronic pain. The compound was well tolerated, with an excellent safety profile.

Clive Dix, Chief Executive Officer of Convergence Pharmaceuticals, commented: "We are really excited to be advancing on schedule to a multiple ascending dose study with this novel, first-in-class treatment for chronic pain.  The data we have seen so far gives us great confidence that CNV2197944 will be a safe and effective long term treatment for chronic pain."

CNV2197944 - a first in class molecule with potential to be a first in class treatment

CNV2197944 is a novel, small molecule, state-dependent calcium channel blocker, designed to selectively inhibit highly active Cav2.2 channels. Preclinical studies demonstrated that CNV2197944 could have analgesic potential for a broad range of chronic pain conditions. Extensive safety and toxicology studies
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
2. Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
5. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
6. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
9. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results and Recent Operational Highlights
11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Applied DNA Sciences, Inc. (OTCQB: ... and product authentication solutions, will host a conference call ... third quarter results. The Quarterly Report on Form 10Q ... of the day on Monday August 11, 2014. ... conference call beginning at 9:00 A.M. Eastern Daylight Time ...
(Date:8/1/2014)... August 01, 2014 RURO, Inc., ... provider, today officially announces the opening of its ... Science Park, Baoshan District in Shanghai, PRC, RURO ... under the management of Mr. Shen Gang, the ... the past three years, RURO’s has installed FreezerPro-based ...
(Date:8/1/2014)... , Aug. 1, 2014 One of the ... of personalized medicine, which is the practice of using ... to a patient,s individual biology. Personalized diagnostics—laboratory analyses that ... role in the lab,s future. This fall, AACC ... the latest science in this exciting field and the ...
(Date:8/1/2014)... Research and Markets has announced the addition ... and Analysis Market 2014-2018" report to their offering. ... Single Nucleotide Polymorphism (SNP) genotyping is the screening and ... of various species. SNPs are commonly present in all ... analyze thousands of SNPs and has the potential for ...
Breaking Biology Technology:Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 3RURO Opens Office in Shanghai, China 2First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2
... COLUMBIA, Md., Dec. 14 A&G Pharmaceutical announced,today ... Initiative,has awarded A&G an $870,000 grant to conduct ... proprietary breast cancer biomarker,GP88, in blood and tissue ... could provide the basis for developing a blood ...
... Embla Systems, a leader in the field of,sleep ... of an,exclusive agreement with the Beth Israel Deaconess ... Pulmonary Coupling (CPC) technology,developed by Drs. Robert Thomas, ... CPC technology represents a breakthrough in how sleep ...
... New Mexico, December 13, 2007In collaboration with the ... international team of researchers has, for the first ... mysterious metallic puddles that facilitate the transition of ... one. , The research may lead to a ...
Cached Biology Technology:A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer 2A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer 3Embla Systems in Collaboration with Beth Israel Deaconess Medical Center to Develop Cardio-Pulmonary Coupling Technology 2Collaboration yields 'the right glasses' for observing mystery behavior in electrons 2Collaboration yields 'the right glasses' for observing mystery behavior in electrons 3
(Date:8/1/2014)... Charan Ranganath of the UC Davis Center for ... National Security Science and Engineering Faculty Fellowship from ... million fellowship will support new work on learning ... UC Davis. , The new project aims to ... with activity in the cortex and hippocampus, brain ...
(Date:8/1/2014)... is tricky enough. Knowing what causes them at the ... of Iowa researchers have created the most detailed map ... long associated with blinding diseases, such as age-related macular ... in the choroid, which supplies blood and oxygen to ... differences in the abundance of proteins in different areas ...
(Date:8/1/2014)... 2014 The Journal of Nutrition Education and Behavior ... Educational Material (GEM) awards, which were presented at the ... "Nutrition Education Impact: Local to Global," in Milwaukee, Wisconsin, ... awards recognize the authors of the best article and ... by members of the JNEB Journal Committee and Board ...
Breaking Biology News(10 mins):A map for eye disease 2
... and Avalon Technology partner on new ... aviation-related ... Inc.,(OTC Bulletin Board: CTHH) ( http://www.catcherinc.com ), a leader ... Technology ( http://www.avalontechnology.com ), a leading,integrator of managed mobile ...
... resulting from higher CO2 could boost the amount ... new study looks at a poorly understood process ... Sayer, postdoctoral fellow at the Smithsonian Tropical Research ... University of Minnesotas Department of Ecology, Evolution and ...
... Boulder, CO, USA Two hundred years ago Lewis and ... deal of scientific research with its descriptions of territory acquired ... be disappointed by the absence of living megafauna, the area ... volume published by the Geological Society of America makes clear ...
Cached Biology News:CATCHER to be Deployed at Major U.S. Airline 2CATCHER to be Deployed at Major U.S. Airline 3CATCHER to be Deployed at Major U.S. Airline 4Complex carbon picture clearer 2
Anti-Human IFN-Gamma Receptor Chain 2 (beta chain) [CD119], Rabbit serum, NON-neutralizing polyclonal antibody...
Anti-BAR Immunogen: Peptide of aa 3-21 from human Bar Available Date: 38226...
... the HECT protein, E6-AP and ... suggests that this E2 is ... of non-""N-end rule"" protein substrates ... proteins as well as the ...
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
Biology Products: